Anxiety and depression in people with post-COVID condition: a Belgian population-based cohort study three months after SARS-CoV-2 infection.
Anxiety
COVID-19
Depression
Post COVID-19 condition
Journal
Social psychiatry and psychiatric epidemiology
ISSN: 1433-9285
Titre abrégé: Soc Psychiatry Psychiatr Epidemiol
Pays: Germany
ID NLM: 8804358
Informations de publication
Date de publication:
31 May 2024
31 May 2024
Historique:
received:
27
01
2023
accepted:
07
03
2024
medline:
31
5
2024
pubmed:
31
5
2024
entrez:
31
5
2024
Statut:
aheadofprint
Résumé
Since the onset of the COVID-19 pandemic, most research has focused on the management of the acute symptoms of the disease. Yet some people tend to experience symptoms beyond the acute phase, defined as Post-COVID-19 Condition (PCC). This study aims to assess the impact of COVID-19 and PCC on anxiety and depression. This is a prospective longitudinal cohort study among the Belgian adult population with recent SARS-CoV-2 infection for which contact tracing was initiated. A total of 3127 people were followed-up just after their infection and three months later (from April 2021 to January 2022). Anxiety and depression were assessed at the two stages using the GAD-7 (Generalized Anxiety Disorder) and the PHQ-9 (Patient Health Questionnaire). Three months after infection, participants with PCC (50%) had an increased probability of having both anxiety and depressive symptoms (p < 0.001). The proportion with anxiety and depressive symptoms at three months were significantly higher in people with PCC (11% and 19%) compared to people without persistent COVID symptoms (3.8% and 4.2%) and to a matched sub-sample not infected with SARS-CoV-2 (6.5% and 4.3%). Having at least one acute COVID-19 symptom (p < 0.001), experiencing financial loss following the infection (p < 0.001), and different PCC symptoms were associated with anxiety and depressive symptoms worsening over time. This study showed that three months after a SARS-CoV-2 infection, one in two people suffer from PCC with significant consequences for their mental health. Follow-up on mental health must therefore have an important place in people suffering from PCC.
Identifiants
pubmed: 38819519
doi: 10.1007/s00127-024-02655-9
pii: 10.1007/s00127-024-02655-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Sciensano
ID : Sciensano (Belgian institute for health) internal funding
Organisme : Sciensano
ID : Sciensano (Belgian institute for health) internal funding
Organisme : Sciensano
ID : Sciensano (Belgian institute for health) internal funding
Organisme : Sciensano
ID : Sciensano (Belgian institute for health) internal funding
Organisme : Sciensano
ID : Sciensano (Belgian institute for health) internal funding
Organisme : Sciensano
ID : Sciensano (Belgian institute for health) internal funding
Organisme : Sciensano
ID : Sciensano (Belgian institute for health) internal funding
Organisme : Sciensano
ID : Sciensano (Belgian institute for health) internal funding
Organisme : Sciensano
ID : Sciensano (Belgian institute for health) internal funding
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Stawicki SP, Jeanmonod R, Miller AC et al (2020) The 2019–2020 Novel coronavirus (severe Acute Respiratory Syndrome Coronavirus 2) pandemic: a Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper. J Glob Infect Dis 12:47–93
doi: 10.4103/jgid.jgid_86_20
pubmed: 32773996
pmcid: 7384689
WHO (2021) A clinical case definition of post COVID-19 condition by a Delphi consensus. World Health Organ (WHO). ; https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 :27
NICE COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020;The National Institute for Health and Care Excellence (NICE):35
Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V et al (2021) Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med 92:55–70
doi: 10.1016/j.ejim.2021.06.009
pubmed: 34167876
pmcid: 8206636
Kessler RC, Aguilar-Gaxiola S, Alonso J et al (2009) The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc 18:23–33
doi: 10.1017/S1121189X00001421
pubmed: 19378696
pmcid: 3039289
Wu T, Jia X, Shi H et al (2021) Prevalence of mental health problems during the COVID-19 pandemic: a systematic review and meta-analysis. J Affect Disord 281:91–98
doi: 10.1016/j.jad.2020.11.117
pubmed: 33310451
Whiteford HA, Degenhardt L, Rehm J et al (2013) Global burden of disease attributable to mental and substance use disorders: findings from the global burden of Disease Study 2010. Lancet 382:1575–1586
doi: 10.1016/S0140-6736(13)61611-6
pubmed: 23993280
Razzouk D Burden and Indirect Costs of Mental Disorders. In: Razzouk D, ed. Mental Health Economics: The Costs and Benefits of Psychiatric Care. Cham: Springer International Publishing 2017:381–91. https://doi.org/10.1007/978-3-319-55266-8_25
For a Healthy Belgium For a Healthy Belgium. https://www.healthybelgium.be/en/ (accessed 18 December 2023)
Afrin LB, Weinstock LB, Molderings GJ (2020) Covid-19 hyperinflammation and post-covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis 100:327–332
doi: 10.1016/j.ijid.2020.09.016
pubmed: 32920235
pmcid: 7529115
Kappelmann N, Dantzer R, Khandaker GM (2021) Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology 131:105295
doi: 10.1016/j.psyneuen.2021.105295
pubmed: 34119855
pmcid: 8172271
Méndez R, Balanzá-Martínez V, Luperdi SC et al (2021) Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. J Intern Med 290:621–631
doi: 10.1111/joim.13262
pubmed: 33533521
pmcid: 8013333
O’Sullivan O (2021) Long-term sequelae following previous coronavirus epidemics. Clin Med (Lond) 21:e68–70
doi: 10.7861/clinmed.2020-0204
pubmed: 33144403
Deng J, Zhou F, Hou W et al (2021) The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci 1486:90–111
doi: 10.1111/nyas.14506
pubmed: 33009668
COVID-19_Weekly_report_FR.pdf https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_Weekly_report_FR.pdf (accessed 12 September 2022)
Smith P, Proesmans K, Van Cauteren D et al (2022) Post COVID-19 condition and its physical, mental and social implications: protocol of a 2-year longitudinal cohort study in the Belgian adult population. Arch Public Health 80:151
doi: 10.1186/s13690-022-00906-2
pubmed: 35659364
pmcid: 9166244
Spitzer RL, Kroenke K, Williams JBW et al (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166:1092–1097
doi: 10.1001/archinte.166.10.1092
pubmed: 16717171
Kroenke K, Spitzer RL, Williams JBW et al (2010) The Patient Health Questionnaire somatic, anxiety, and depressive Symptom scales: a systematic review. Gen Hosp Psychiatry 32:345–359
doi: 10.1016/j.genhosppsych.2010.03.006
pubmed: 20633738
Plummer F, Manea L, Trepel D et al (2016) Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry 39:24–31
doi: 10.1016/j.genhosppsych.2015.11.005
pubmed: 26719105
Spitzer RL, Kroenke K, Williams JB (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of Mental disorders. Patient Health Questionnaire JAMA 282:1737–1744
pubmed: 10568646
Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16:606–613
doi: 10.1046/j.1525-1497.2001.016009606.x
pubmed: 11556941
pmcid: 1495268
Manea L, Gilbody S, McMillan D (2012) Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. CMAJ 184:E191–196
doi: 10.1503/cmaj.110829
pubmed: 22184363
pmcid: 3281183
Löwe B, Decker O, Müller S et al (2008) Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. Med Care 46:266–274
doi: 10.1097/MLR.0b013e318160d093
pubmed: 18388841
Riepenhausen A, Veer IM, Wackerhagen C et al (2022) Coping with COVID: risk and resilience factors for mental health in a German representative panel study. Psychol Med. ;1–11
Murillo LA, Follo E, Smith A et al (2020) Evaluating the effectiveness of Online Educational Modules and interactive Workshops in alleviating symptoms of mild to Moderate Depression: a pilot trial. J Prim Care Community Health 11:2150132720971158
doi: 10.1177/2150132720971158
pubmed: 33225804
pmcid: 7686590
Parrish JM, Jenkins NW, Cha EDK et al (2022) Epidemiological Relevance of Elevated Preoperative Patient Health Questionnaire-9 scores on clinical improvement following lumbar decompression. Int J Spine Surg 16:159–167
doi: 10.14444/8184
pubmed: 35314511
pmcid: 9519078
HAS Covid long: les recommandations de la Haute Autorité de santé. 2021;Haute Autorité de Santé (HAS):2
Chopra V, Flanders SA, O’Malley M et al (2021) Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med 174:576–578
doi: 10.7326/M20-5661
pubmed: 33175566
Han Q, Zheng B, Daines L et al (2022) Long-term sequelae of COVID-19: a systematic review and Meta-analysis of one-year Follow-Up studies on Post-COVID symptoms. Pathogens 11:269
doi: 10.3390/pathogens11020269
pubmed: 35215212
pmcid: 8875269
Ismael F, Bizario JCS, Battagin T et al (2020) Post-infection depressive, anxiety and post-traumatic stress symptoms: a retrospective cohort study with mild COVID-19 patients. https://doi.org/10.1101/2020.08.25.20182113
Bruggeman H, Smith P, Berete F et al (2022) Anxiety and depression in Belgium during the First 15 months of the COVID-19 pandemic: a longitudinal study. Behav Sci 12:141
doi: 10.3390/bs12050141
pubmed: 35621438
pmcid: 9137576
Ismael F, Bizario JCS, Battagin T et al (2021) Post-infection depressive, anxiety and post-traumatic stress symptoms: a prospective cohort study in patients with mild COVID-19. Prog Neuropsychopharmacol Biol Psychiatry 111:110341
doi: 10.1016/j.pnpbp.2021.110341
pubmed: 33940097
pmcid: 8086265
Fernández-de-las-Peñas C, Pellicer-Valero OJ, Navarro-Pardo E et al (2021) The number of symptoms at the acute COVID-19 phase is associated with anxiety and depressive long-term post-COVID symptoms: a multicenter study. J Psychosom Res 150:110625
doi: 10.1016/j.jpsychores.2021.110625
pubmed: 34563747
pmcid: 8455234
Kong X, Zheng K, Tang M et al (2020) Prevalence and Factors Associated with Depression and anxiety of hospitalized patients with COVID-19. medRxiv. ;2020.03.24.20043075.
Griffiths D, Sheehan L, van Vreden C et al (2021) The impact of work loss on Mental and Physical Health during the COVID-19 pandemic: baseline findings from a prospective cohort study. J Occup Rehabil 31:455–462
doi: 10.1007/s10926-021-09958-7
pubmed: 33656699
pmcid: 7926060
Czysz AH, Nandy K, Hughes JL et al (2021) Impact of the COVID-19 pandemic on adults with current and prior depression: initial findings from the longitudinal Texas RAD study. J Affect Disord 294:103–108
doi: 10.1016/j.jad.2021.06.071
pubmed: 34274785
pmcid: 8433599
Puchner B, Sahanic S, Kirchmair R et al (2021) Beneficial effects of multi-disciplinary rehabilitation in postacute COVID-19: an observational cohort study. Eur J Phys Rehabil Med 57:189–198
doi: 10.23736/S1973-9087.21.06549-7
pubmed: 33448756
Al-Jabr H, Hawke LD, Thompson DR et al (2023) Interventions to support mental health in people with long COVID: a scoping review. BMC Public Health 23:1186
doi: 10.1186/s12889-023-16079-8
pubmed: 37340400
pmcid: 10280822
Jaffri A, Jaffri UA (2020) Post-intensive care syndrome and COVID-19: crisis after a crisis? Heart Lung: J Cardiopulm Acute Care 49:883–884
doi: 10.1016/j.hrtlng.2020.06.006
Wittkampf K, van Ravesteijn H, Baas K et al (2009) The accuracy of Patient Health Questionnaire-9 in detecting depression and measuring depression severity in high-risk groups in primary care. Gen Hosp Psychiatry 31:451–459
doi: 10.1016/j.genhosppsych.2009.06.001
pubmed: 19703639